CHA Biotech announced on the 28th that its early ovarian failure treatment ‘CBT210-POI’ has been confirmed for safety and tolerability in a phase 1 clinical trial in South Korea. Early ovarian failure is a condition where ovarian function declines, making it difficult to conceive. It affects 1% of women of childbearing age under 40. The component of CBT210-POI is derived from umbilical cord stem cells. It was selected as a project for government support for regenerative medicine technology development in 2021.
Seoul National University Hospital announced on the 28th that the implementation of a post-operative recovery improvement program ‘ERAS’ for colorectal cancer patients resulted in an average hospital stay reduction of 2 days. Patients typically undergo surgery, fast, or receive narcotic analgesics to reduce pain. The hospital minimized the fasting period and use of analgesics for patients. As a result, the average hospital stay for colorectal cancer surgery patients decreased from 5 days to 3 days. The rate of complications or admissions to the intensive care unit was 0%.
Dong-A Pharmaceutical announced on the 28th that its factory in Cheonan has signed a business agreement with Cheonan City to establish a ‘paper pack recovery and utilization circulation system.’ The city will distribute collection nets to enable the separate disposal of paper packs in dwellings. Once the collection company retrieves the paper packs, Dong-A Pharmaceutical will reprocess them for use in product packaging.
Lunit announced on the 28th that its artificial intelligence (AI) system for diagnosing chest X-rays, ‘Lunit Insight CXR4,’ has received certification under the European Union (EU) medical device regulation. Beyond simply detecting diseases with AI, it has enhanced reading efficiency. Lunit plans to expand the introduction of its products to hospitals in Europe.
The Korea Disease Control and Prevention Agency announced on the 28th that it will publish the operational guidelines for national standard laboratories for infectious diseases in both Korean and English. The guidelines explain procedures for testing and diagnosing infectious diseases like influenza in laboratories. They also include the equipment, personnel, and environmental standards that laboratories must meet. The agency expects the testing capabilities for infectious diseases to improve.